West Pharma Launches Vial2Bag Advanced Admixture Device to Enhance Patient Care

The device is needle-free and is suitable for immediate use. It can optimise the time spent in pharmacy clean rooms and assist in standardising admixture systems to maximise the efficiency of point-of-care nursing.

Global Pharmaceutical player, West Pharma has launched a new device called the Vial2Bag Advanced 13mm admixture device that makes it easier and safer to prepare IV medications, leading to better care for patients.

The newly launched Vial2Bag Advanced 13mm admixture device is designed to transfer drugs safely and efficiently from vials to IV bags which helps to reduce the risk of contamination. Further, this device has also been approved by the US Food and Drug Administration (FDA).

Moreover, the device is needle-free and is suitable for immediate use. It can optimise the time spent in pharmacy clean rooms and assist in standardising admixture systems to maximise the efficiency of point-of-care nursing.

Sharing thoughts on the same, Cindy Reiss-Clark, chief commercial officer, West Pharma, said, "This year, West celebrates 100 years as an industry leader and scientific innovator in high-quality injectable solutions. The 13mm product is a key addition to our administration system portfolio, addressing the critical need for more drug preparation and delivery options at the point-of-care."

Founded in 1923 by Herman O West and JR Wike of Philadelphia, West Pharmaceutical Services, Inc, commonly known as West Pharma, is a leading global manufacturer in the design and production of technologically advanced, high-quality, integrated containment and delivery systems for injectable medicines.

The US-based company is in association with the world’s top pharmaceutical and biotechnology companies, working alongside them to improve patient health.

In a similar development, Clarivate launched the VeriSIM Life Translational Index to enhance drug discovery intelligence. This integrated workflow aims to offer diverse predictive insights into compound safety and efficacy, including bioavailability, hepatic and renal clearance, clinical toxicity, first-in-human dose, and more.

The introduction of this innovative solution represents the next phase of the expanding collaboration between Clarivate and VeriSIM Life, a leading AI-enabled platform focused on de-risking breakthrough drug development.

Days back, AstraZeneca and Absci joined hands in a $247 million cancer drug deal. The partnership sought to leverage Absci's Al technology for large-scale protein analysis to find a viable oncology therapy, a leading focus of AstraZeneca. However, the companies didn’t specify the type of cancer they plan to target.